GlassScriptPhysician profile
Lalitha D Reddy
NPI 1053306597
$10,240.92
in general payments reported to CMS, 2019-2025
37 companies · $1,750 in 2025
The $1,750 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $725 · 2021: $1,002 · 2022: $1,859 · 2023: $2,055 · 2024: $1,891 · 2025: $1,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,323 · Education: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,323.43 |
| Education | $372.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,479.96 | 2019-2025 | |
| Janssen Biotech, INC. | $1,378.17 | 2019-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $781.09 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $738.16 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $556.28 | 2019-2025 | |
| Lilly USA, LLC | $540.00 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $507.39 | 2019-2025 | Bimzelx |
| Merz North America, INC. | $416.71 | 2019-2023 | |
| Genzyme Corporation | $353.41 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $343.65 | 2019-2025 | Ilumya |
| Galderma Laboratories, L.P. | $226.50 | 2019-2025 | Aklief, Nemluvio |
| Incyte Corporation | $208.68 | 2021-2024 | Opzelura |
| Amgen INC. | $162.48 | 2022-2023 | Otezla |
| Angiodynamics, INC. | $153.95 | 2020-2025 | Auryon Laser System 100-120 Vac |
| E.R. Squibb & Sons, L.L.C. | $149.93 | 2022-2024 | Sotyktu |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $149.78 | 2021-2023 | Venaseal |
| Dermavant Sciences, INC. | $137.22 | 2023-2024 | Vtama |
| Leo Pharma INC. | $134.67 | 2021-2025 | Adbry |
| Mayne Pharma Commercial LLC | $120.67 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $84.04 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $73.87 | 2021 | |
| Almirall LLC | $63.40 | 2019-2021 | |
| Organon LLC | $63.30 | 2025 | Hadlima, Vtama |
| Fresenius Kabi USA, LLC | $60.94 | 2023-2024 | Idacio |
| Medtronic Vascular, INC. | $54.03 | 2020 | |
| Encore Dermatology INC. | $50.92 | 2019 | |
| Celgene Corporation | $42.03 | 2019 | |
| Sanofi-Aventis U.S. LLC | $36.94 | 2021 | |
| Journey Medical Corporation | $29.51 | 2024-2025 | |
| Mission Pharmacal Company | $27.37 | 2019 | |
| Verrica Pharmaceuticals INC. | $25.50 | 2024 | Ycanth |
| Dermira, INC. | $22.03 | 2021 | |
| Prugen, INC. Pharmaceuticals | $18.55 | 2019 | |
| Arcutis Biotherapeutics, INC. | $15.88 | 2024 | Zoryve |
| Strata Skin Sciences, INC. | $13.41 | 2024 | Xtrac |
| Merck Sharp & Dohme LLC | $12.43 | 2019 | |
| Sensus Healthcare, INC. | $8.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lalitha Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.